Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its blockbuster molecule tirzepatide. Now, with a pipeline chock-full of ...

Eli Lilly expands its partnership with AdvanCell to advance targeted alpha therapies using Pb-212 technology for cancer treatment. Lilly inks a global licensing deal with OliX for OLX75016 ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...

Feb 5 (Reuters) - Eli Lilly (LLY.N), opens new tab investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales of popular weight-loss drug ...

Eli Lilly's Q4 revenue rose 45% YoY to $13.53B, driven by Mounjaro and Zepbound. Adjusted EPS hit $5.32, beating the $4.94 consensus. 2025 guidance projects $58B-$61B in sales, with a 32% growth ...

You might be familiar with the top sellers, such as Eli Lilly's Zepbound or Novo ... That said, this newer biotech player could eventually carve out a spot if all continues to go well in clinical ...

You might be familiar with the top sellers, such as Eli Lilly's Zepbound or Novo Nordisk's Wegovy -- they've made headlines as demand for them soared. In fact, demand for these drugs has been so ...